Olympus Corp. shares tumbled as much as 17% in Tokyo after the US FDA issued a warning letter regarding quality management system issues at six of its facilities. The letter follows inspections conducted in late 2025. Olympus stated the warning will not disrupt production or impact financial results, and it plans to respond within 15 business days.
Jefferies analysts noted the letter confirms systemic quality issues, disappointing investors who had hoped corrective actions were accepted. This marks the second major FDA-related stock drop for Olympus in 2025, following a 12% plunge in June after import alerts were issued on devices from its Japanese unit.
উৎস: Bloomberg Markets · সারাংশ: HeadlinesBriefing